NEW YORK, March 27, 2014 /PRNewswire/ -- Across the
globe, there are over 13 million new cancer cases each year. By
2030, it is estimated by the International Agency for Research on
Cancer (IARC) that there will be approximately 21.4 million new
cancer cases and 13.2 million cancer deaths worldwide. Some of the
more common (and deadly) forms of cancer are head and neck cancer,
which account for approximately 600,000 new cases worldwide each
year and result in a five-year survival rate of around 30%. One
company that is actively trying to fight this disease is CEL-SCI
Corporation (NYSE-MKT: CVM).
CEL-SCI Corporation (CVM) is engaged in the research and
development of drugs and vaccines, and is currently in a Phase III
clinical trial directed at using the immune system to produce an
anti-tumor immune response against primary head and neck cancer.
Multikine (Leukocyte Interleukin, Injection) has been cleared by
regulators in eleven countries around the world, including the FDA
in the US, for this Phase III trial following encouraging results
from both Phase I and II trials. Multikine is a different kind of
investigational therapy in which immunotherapy is given to cancer
patients first (prior to them receiving any conventional treatment
for cancer, i.e. surgery, radiation, and/or
chemotherapy).
A full in-depth analyst report on CVM that includes risk
factors, industry review, financial position, potential revenues,
review of current business model, competition breakdown, analyst
summary, and recommendation can be viewed by using the following
link at no cost:
http://bit.ly/CVM-AnalystReport
copy and paste to browser may be required
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking
statements and information, as defined within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and is subject to the Safe Harbor
created by those sections. This material contains statements about
expected future events and/or financial results that are
forward-looking in nature and subject to risks and uncertainties.
Such forward-looking statements by definition involve risks,
uncertainties and other factors, which may cause the actual
results, performance or achievements of companies mentioned to be
materially different from the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. Information in this release is fact checked and produced on
a best efforts basis by Michael
Maggi, Chartered Financial Analyst. An outsourced research
services provider represented by Michael
Maggi, CFA, provided Small Cap Street, LLC this article or
report. However, we are only human and are prone to make mistakes.
If you notice any errors or omissions, please notify us below.
Small Cap Street, LLC is not entitled to veto, interfere or alter
the articles, documents or report once created and reviewed by the
outsourced research provider represented by Michael Maggi, CFA. Small Cap Street, LLC is the
party responsible for issuing the press release and for hosting the
full analyst report on smallcapir.com. Michael Maggi, Chartered Financial Analyst, is
the author of research report. This information is submitted to
increase awareness for mentioned companies to the public.
If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at admin@smallcapstreet.com. For any urgent concerns or inquiries,
please contact us at admin@smallcapstreet.com.
NOT FINANCIAL ADVICE
Small Cap Street, LLC makes no warranty, expressed or implied,
as to the accuracy or completeness or fitness for a purpose
(investment or otherwise), of the information provided in this
document. This information is not to be construed as personal
financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold
any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Small Cap Street, LLC is not responsible for any error which may
be occasioned at the time of printing of this document or any
error, mistake or shortcoming. Small Cap Street, LLC has
compensated Michael Maggi, CFA,
two hundred dollars for the right to
disseminate analyst report. No liability is accepted by Small Cap
Street, LLC whatsoever for any direct, indirect or consequential
loss arising from the use of this document. Small Cap Street, LLC
expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Small Cap Street, LLC
does not (1) guarantee the accuracy, timeliness, completeness or
correct sequencing of the information, or (2) warrant any results
from use of the information. The included information is subject to
change without notice. Views expressed in analyst report are not
the opinion of Small Cap Street, LLC.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Small Cap Street, LLC